PET Imaging of New Target PARP in Prostate Cancer. [PDF]
Yang Z +6 more
europepmc +1 more source
The Double-Edged Role of Enzyme Inhibition in Oral Anticancer Therapy. [PDF]
Assiri AA.
europepmc +1 more source
PARP inhibitors in the treatment of ovarian cancer: a narrative review. [PDF]
Wang Y +8 more
europepmc +1 more source
Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? [PDF]
Kumari S, Umadevi K, Sundeep D.
europepmc +1 more source
Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells. [PDF]
Perez JM +3 more
europepmc +1 more source
PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines. [PDF]
Huart C +7 more
europepmc +1 more source
Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis. [PDF]
Liu Y +5 more
europepmc +1 more source
MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling. [PDF]
Gundogdu R.
europepmc +1 more source
Roles of ADP-Ribosyltransferases in Cancer. [PDF]
Veilleux M, Nguyen A, Cao C, Shi Y.
europepmc +1 more source
The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. [PDF]
Al-Ani M +15 more
europepmc +1 more source

